Phase II trial of neoadjuvant docetaxel and CG1940/CG8711 followed by radical prostatectomy in patients with high-risk, clinically localized prostate cancer.
Latest Information Update: 31 Jan 2011
Price :
$35 *
At a glance
- Drugs Docetaxel (Primary) ; Tumour cell vaccine-GVAX (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- 15 Oct 2008 Actual patient number (6) added as reported by ClinicalTrials.gov.
- 15 Oct 2008 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 21 Jun 2008 Status changed from initiated to recruiting.